Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Abbott Features Novel Biomarkers and Laboratory Automation at International Federation of Clinical Chemistry Congress


      News provided by

      Abbott

      14 May, 2011, 06:00 GMT

      Share this article

      Share this article


      DELKENHEIM, Germany, May 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today the company's schedule of key workshops and scientific presentations at the International Federation of Clinical Chemistry and Laboratory Medicine Congress (IFCC), May 15-19, in Berlin, Germany. The company will sponsor five scientific industry workshops covering a range of clinical diagnostic research in areas such as heart and renal disease, cancer, hepatitis, and vitamins D and active B12. The company also will present its total customer solution offering for Information Technology (IT), automation, e-learning and instrument demonstrations at the Abbott exhibit booth (Hall 13).

      "As a global leader in diagnostics, Abbott is committed to scientific excellence and developing technologies and customer-focused solutions that enable laboratories to be more efficient and provide better clinical outcomes," said Brian Blaser, senior vice president, Diagnostics, Abbott. "The IFCC meeting will provide Abbott the platform to showcase many of the solutions we offer our customers to address the increasing demands on the lab."

          
          Abbott's IFCC Workshops (all times are Central European)
          --------------------------------------------------------
      
          -- Importance of Biomarkers in Optimizing the Treatment of
             Patients with Heart and Kidney Disease, May 16, 13:00 to
             14:00 p.m., Hall 7
      
             Nicolas Mills, M.D., Ph.D., a cardiologist at the British
             Heart Foundation Centre for Cardiovascular Science and
             Simon Walker, M.D., Ph.D., a senior lecturer and honorary
             consultant in Clinical Biochemistry in the Department of
             Clinical Biochemistry at Edinburgh University, will discuss
             their recently published research in the Journal of the
             American Medical Association (JAMA) demonstrating that for
             patients with suspected acute coronary syndrome (ACS), the
             use of more sensitive troponin assays can increase
             diagnosis of myocardial infarction (MI) by a third. The
             ARCHITECT Troponin assay can identify patients who would
             not have received treatment for myocardial infarction, but
             were at high risk of recurrent MI and death.
      
             Implementation of this assay and diagnostic reclassification
             of these patients was associated with improved clinical
             management, fewer death and fewer admissions with recurrent
             MI.
      
             Kai M. Schmidt-Ott, M.D., Charite Universitatsmedizin in
             Berlin, will also review results of a multi-center study
             in Europe and the United States of emergency department
             patients tested for neutrophil gelatinase-associated
             lipocalin (NGAL). The research showed that urine NGAL
             facilitates an early diagnosis of acute kidney injury (AKI)
             and can distinguish pre-renal from intrinsic acute kidney
             injury.
      
             AKI is a major cause of renal failure and must be diagnosed
             quickly to prevent kidney damage. Urine NGAL levels, alone
             or when combined with other clinical information, will be
             important for optimal patient management and for the
             development of novel therapeutic strategies based on an
             early detection of AKI. Per Venge, M.D., Ph.D., Head of
             the Department of Medical Sciences, Clinical Chemistry,
             University Hospital Uppsala in Sweden, will chair the
             workshop.
      
          -- Ovarian Cancer Biomarkers in the Clinical Context:
             Stratification and Monitoring, May 16, 16:45 to 17:45 h,
             Hall 7
      
             Jalid Sehouli, M.D., from University Hospital Charite in
             Berlin, will discuss why an optimal referral of ovarian
             cancer patients based on their cancer risk can improve
             survival rates. Inga Laursen, M.D. from Statens Serum
             Institut in Copenhagen, will review a prospective study
             designed to validate the Risk of Ovarian Malignancy
             Algorithm (ROMA), a combined use of HE4 and another cancer
             marker, CA125, for identifying patients at risk for ovarian
             malignancies. Christian Marth, M.D., Medical University of
             Innsbruck, will discuss the role of the ovarian cancer
             biomarker CA125 in follow-up monitoring of patients.
      
          -- Laboratory Diagnosis of Hepatitis C: What Are We Looking
             For?
      
             May 17, 13:00 to 14:00 p.m., Hall 7
      
             Jacques Izopet, Ph.D., PharmD, from the University of
             Toulouse, France will summarize current knowledge on HCV
             infections, especially in immunocompromised patients.
      
             Additionally, Paul Holder, MSc, clinical scientist at
             University College Dublin, will present data on the
             ARCHITECT HCV antigen assay, and its ability to detect
             cases missed by HCV-antibody tests alone. In Ireland, HCV
             Ag testing has recently been added to the set of markers
             used to test patients requiring regular hemodialysis and
             other high-risk groups to prevent infections in the
             antibody negative diagnostic window. Moreover, the assay is
             used to confirm an active disease in HCV antibody positive
             samples and can help to reduce costs for other confirmatory
             assays such as immunoblot assays.
      
          -- Automation and Workflow Improvement To Ensure Your Lab's
             Efficiency,
      
             May 17, 16:45 to 17:45 h, Hall 7
      
             Matthias Orth, M.D., Marienhospital, Stuttgart, will provide
             an overview of the workflow and cost benefits of automated
             immunoassay systems. Mats Nybo, M.D. will discuss the
             implementation and adoption Abbott's Total Laboratory
             Automation System and how it increased efficiency and
             helped to deliver improvements and productivity for Odense
             Universiteshospital in Denmark.
      
          -- Vitamin D and B12: Immunoassays in Preventative Medicine,
      
             May 18, 13:00 to 14:00 h, Hall 7
      
             Etienne Cavalier, Ph.D., University Hospital of Liege,
             Belgium, will review data on the performance of Abbott's
             ARCHITECT 25-OH Vitamin D Assay. The benefits of the Abbott
             test will be compared with other vitamin D test methods.
             Wolfgang Herrmann, M.D., Ph.D., Saarland University,
             Germany, will report data showing that a specific test for
             the biologically active form of B12 may provide earlier
             detection of individuals at risk for B12 deficiency.
      
          Abbott will also participate in an IFCC-sponsored workshop hosted
          by IFCC President Graham Beastall, Ph.D. about the value of
          laboratories and best practices.
      
          -- Adding Value to the Laboratory (IFCC-sponsored):
      
             May 19, 13:00-14:00 h, Hall 8
      
             Sarah Jarvis, principal Clinical Biochemist at Wishaw
             General Hospital in NHS Lanarkshire, U.K., will host a
             discussion of best practices from the U.K. and highlight
             activities from National Pathology Week which promote the
             importance of laboratory professionals to the healthcare
             community. Dr. Graham Beastall, Ph.D. president of IFCC,
             will present on good practices among laboratories and the
             importance of lab professionals engaging with other health
             care practitioners to improve patient care.
      

      About Abbott Diagnostics

      Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 69,000 customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs.

      About Abbott

      Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.

      Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

      Modal title

      Also from this source

      Abbott's Cologuard Plus® receives CE Mark for colorectal cancer screening in Europe

      Abbott's Cologuard Plus® receives CE Mark for colorectal cancer screening in Europe

      Abbott, a global healthcare leader, announced today that the Cologuard Plus® test has received CE Mark under the European Union's In Vitro Diagnostic ...

      Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

      Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes

      Abbott (NYSE: ABT), a global healthcare leader, announced today it has secured CE Mark for the world's first dual glucose–ketone sensing technology...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Medical Equipment

      Medical Equipment

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.